Michael Demetriou

Title: Michael Demetriou: Innovator in Cancer Treatment

Introduction

Michael Demetriou is a prominent inventor based in Irvine, California, known for his significant contributions to the field of immunotherapy and cancer treatment. With a total of 10 patents to his name, Demetriou has made remarkable strides in developing innovative therapeutic solutions.

Latest Patents

Among his latest patents, one notable invention is related to glycan-dependent immunotherapeutic molecules. This invention focuses on compositions and methods for treating cancer, utilizing peptides, nucleic acids encoding such peptides, and cells expressing these peptides. The peptide comprises a tumor-associated carbohydrate antigen (TACA)-binding domain, which plays a crucial role in targeting cancer cells. Another significant patent involves analogs of N-acetylglucosamine, which presents a novel method for treating or preventing diseases associated with low levels of branched N-glycans. This method includes administering an effective amount of a compound to subjects in need, potentially in conjunction with additional therapeutic agents.

Career Highlights

Throughout his career, Michael Demetriou has worked with esteemed institutions such as Mount Sinai Hospital Corporation and the University of California. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Demetriou has collaborated with notable colleagues, including James W. Dennis and Raymond Wenhou Zhou. These partnerships have further enhanced his research and development efforts in the realm of immunotherapy.

Conclusion

Michael Demetriou's innovative work in cancer treatment through his patents and collaborations highlights his dedication to advancing medical science. His contributions continue to pave the way for new therapeutic approaches in the fight against cancer.